GSK plc（GSK）重大事項與業績發布
| 申報日 | 表別 | 事項 | 原文 |
|---|---|---|---|
| 2026-10-08 | 6-K | WENDY BECKER CBE - NEW DIRECTORSHIP | SEC |
| 2026-10-06 | 6-K | ADMISSION TO TRADING | SEC |
| 2026-10-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-09-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-15 | 6-K | — | SEC |
| 2026-09-15 | 6-K | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | SEC |
| 2026-09-14 | 6-K | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC | SEC |
| 2026-09-14 | 6-K | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA | SEC |
| 2026-09-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-10 | 6-K | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE | SEC |
| 2026-09-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-08 | 6-K | — | SEC |
| 2026-09-01 | 6-K | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III | SEC |
| 2026-09-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-08-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-24 | 6-K | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER | SEC |
| 2026-08-24 | 6-K | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN | SEC |
| 2026-08-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-07-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-28 | 6-K | 2ND QUARTER RESULTS | SEC |
| 2026-07-28 | 6-K | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ | SEC |
| 2026-07-28 | 6-K | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE | SEC |
| 2026-07-24 | 6-K | ADMISSION TO TRADING | SEC |
| 2026-07-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-22 | 6-K | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS | SEC |
| 2026-07-20 | 6-K | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE | SEC |
| 2026-07-17 | 6-K | CAMLIPIXANT PHASE III RESULTS UPDATE | SEC |
| 2026-07-17 | 6-K | AUDIT TENDER CONCLUSION | SEC |
| 2026-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-15 | 6-K | GSK COMPLETES ACQUISITION OF NUVALENT, INC | SEC |
| 2026-07-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-13 | 6-K | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER | SEC |
| 2026-07-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-10 | 6-K | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ | SEC |
| 2026-07-09 | 6-K | DIRECTORATE CHANGE | SEC |
| 2026-07-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-06-29 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2026-06-29 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-26 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2026-06-24 | 6-K | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT | SEC |
| 2026-06-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-22 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-17 | 6-K | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA | SEC |
| 2026-06-15 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-12 | 6-K | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS | SEC |
| 2026-06-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-09 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. | SEC |
| 2026-06-09 | 6-K | DR HAL BARRON - NEW DIRECTORSHIP | SEC |
| 2026-06-08 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-01 | 6-K | TRANSACTION IN OWN SHARES | SEC |
資料來自 SEC EDGAR 的 8-K／6-K 申報。8-K 是美國國內發行人的重大事項揭露（Item 2.02 為業績發布）；6-K 是外國發行人（含 ADR）的對應形式。本站僅整理連結，原文一律在 SEC 網站。「影音」是公司新聞稿載明的法說會 webcast 網址，「投資人頁」是新聞稿指向的公司投資人關係頁；重播通常只保留一段時間，過期與否以該網頁為準。法說會時間取自同一份新聞稿，為美國當地時間（ET 美東、CT 美中、MT 山區、PT 太平洋）。